Rumi Therapeutics

Rumi Therapeutics is a drug-development company operating within Rumi Scientific Holdings, alongside its sister company Rumi Scientific. The company is focused on advancing therapeutic candidates for neurological and neurodevelopmental disorders toward clinical evaluation. Its lead program is RTX-7340 (formerly ENT-7340), an investigational, IND-ready phosphodiesterase 2A (PDE2A) inhibitor optioned from Enthorin Therapeutics for the treatment of Fragile X syndrome. Rumi Therapeutics leverages Rumi Scientific's proprietary human organoid platform and translational neurophysiological endpoints to bridge the gap between preclinical disease models and clinical development. Additionally, the company's pipeline includes a preclinical bromodomain-containing protein 9 (BRD9) inhibitor for Huntington's disease.